Therapy Areas: Diabetes
Ascletis to discuss ASC36_35 FDC preclinical weight loss data at EASD annual meeting
23 July 2026 - Biotechnology company Ascletis Pharma Inc (HKEX:1672) announced on Wednesday that preclinical data of ASC36_35 FDC, a once-monthly injection co-formulation of ASC36, a peptide amylin re...
Arch Biopartners engages private lab to advance IL-32 chronic kidney disease programme
20 July 2026 - Canada-based biotechnology company Arch Biopartners Inc (TSX-V:ARCH) (OTCQB:ACHFF) announced on Friday that it has engaged a US-based laboratory specialising in bioengineering to accele...
Lakewood-Amedex Biotherapeutics reports positive Nu-3 Gel preclinical safety data for upcoming Phase 2a trial
16 July 2026 - Clinical-stage biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT) on Wednesday announced preclinical safety data for its Nu-3 gel formulation that establishes a str...
Insulet expands European footprint with Omnipod 5 and Omnipod Discover launch in Spain
6 July 2026 - Medical device company Insulet Corporation (NASDAQ:PODD) announced on Monday the launch of its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, ma...
LyGenesis granted funding for research project to induce immune tolerance to pancreatic islet transplantation
26 June 2026 - LyGenesis, Inc., a US-based, clinical-stage biotechnology company developing cell therapies for organ regeneration, announced on Thursday that it has received a research award from Brea...
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
25 June 2026 - Cirius Therapeutics Inc, a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, announced on Wednesday that e...